Skip to main content
OpenTrials
Completed

NCT Number: NCT03914716

Imaging of Arthropathy in Boys With Hemophilia in China

Hemophilia is a genetic condition characterized by marked phenotypic heterogeneity. Bleeding into a joint is the single most important risk factor for the development of hemophilic arthropathy (HA). It is thought that clinical and imaging manifestations of HA are at least partially attributable to genetic polymorphisms unrelated to the hemophilia genotype. Identifying and characterizing biologic factors that could explain differences in susceptibility to joint degeneration of patients with hemophilia would help stratify patients according to the risk of degeneration of their joints and develop personalized therapeutic and prophylactic strategies. This study is conducted in China.

Completed

Looking for future studies?

Notify Me

Key information

About this study

This will be a 3-year prospective cohort study conducted in a single centre (Beijing Children's Hospital, BCH, China) with a 2-year follow-up of patients Index joints (ankles, elbows and knees) of young Chinese boys with hemophilia A will be evaluated as follows: physical examination every 6 months using the Hemophilia Joint Health Score [HJHS], ultrasound imaging (gray-scale and color Doppler ultrasound [US]), and by laboratory (serum) at baseline, at 6, and 24 months. Magnetic resonance imaging (MRI) scans of index joints will be obtained at baseline, and 24 months. Features that will be captured either quantitatively or semantically in the imaging scans will be aggregated to generate "imaging phenotypes" which will be associated with clusters of co-expressed genes (metagenes) and clinical data.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hemophilia A with baseline FVIII levels of <2%
  • Clinical history of ≥ 50 exposure days to FVIII prior to the study start.
  • On-demand treatment, prophylaxis FVIII infusions or treatment with plasma-derived products for >3 months prior to enrollment into the study.

Exclusion criteria

  • History of FVIII inhibitor (titer >0.6 Bethesda Units [BU])
  • Chronic renal failure (serum creatinine >2.0 mg /dL).
  • Chronic liver disease (alanine aminotransferase [ALT] >200 U/L).
  • Clinically documented immunodeficiency.
  • Anticipation of need for major surgery during the study period.
  • Association of diseases known to mimic or cause joint diseases such as symptomatic human immunodeficiency virus (HIV) infection, juvenile idiopathic arthritis, and metabolic bone diseases.
  • Social barriers for participation in the study such as long distance between home and the comprehensive care centre, and documented track record of non-compliance to therapies or participation in clinical studies.
  • Neuro-developmental/behavioral problems.
  • Contraindications to MR imaging (presence of heart pacemakers, metallic foreign bodies in the eye, aneurysm clips, severe claustrophobia).

Treatment and study plan

Study group

Diagnostic Test

Subjects will have physical, imaging examinations and provide samples for biological markers

Primary outcomes

  1. Annualized total index joint bleeding rates (AJBRs)

    Time frame: Between baseline and 24 months

    AJBRs will be calculated from prospectively collected joint bleeding logs and clinic records.

Secondary outcomes

  1. Number of participants with joint inflammation

    Time frame: At baseline, 6 months and 24 months

    Assessed by ultrasound

  2. Number of participants with joint inflammation

    Time frame: Between baseline and 24 months

    Assessed by MRI of the joints

  3. Number of participants with joint damage

    Time frame: At baseline, 6 months and 24 months

    Assessed by ultrasound

  4. Number of participants with joint damage

    Time frame: Between baseline and 24 months

    Assessed by MRI of the joints

  5. Number of participants with clinical arthropathy

    Time frame: Every 6 months

    Assessed by the Hemophilia Joint Health Score tool (HJHS), version 2.1 - Joint score range: 0 (normal) to 16 (worse outcome).

  6. Presence of inflammatory biomarkers in plasma

    Time frame: At baseline, 6 months and 24 months

    Measured by ELISA (enzyme-linked immunosorbent assay)

  7. Internal MRI-based soft tissue score change

    Time frame: Between baseline and 24 months

    Assessed by the 17-point International Prophylaxis Study Group (IPSG) MRI scale. Score range: 0 to 17 (worse outcome)

  8. Internal MRI-based osteochondral tissue score change

    Time frame: Between baseline and 24 months

    Assessed by the 17-point International Prophylaxis Study Group (IPSG) MRI scale. Score range: 0 to 17 (worse outcome)

Sponsors and collaborators

Lead sponsor

Andrea Doria

Other

Collaborators

  • Beijing Children's Hospital, Baxalta US Inc.

Registry information

Official study title

Radiogenomics: Personalized Imaging of Arthropathy in Boys With Hemophilia in China

Important dates

Study start
2018
Primary completion
2022
Study completion
2023
First posted
Apr 16, 2019
Registry last updated
Apr 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.